Bracco Diagnostics

Bracco Diagnostics (3099), a member of the Bracco Group, is displaying Isovue and CardioGen-82, as well as the Acist CVi Contrast Management System.

Isovue is nonionic contrast agent, which has received FDA-approval for a range of diagnostic and interventional indications, and provides a range of iodine concentrations and packaging options. CardioGen-82 is a generator-based PET agent reimbursed for the evaluation of coronary artery disease.

The Acist CVi Contrast Management System is a fully automated contrast delivery system that streamlines angiographic procedures. The Acist CVi System features: cardiac and vascular procedure protocols; continuous, in-line hemodynamic monitoring; x-ray image synchronization with many manufacturers; automatic syringe refill from contrast source into multi-use syringe; flexible, low profile equipment configuration (on table or cart); and system feedback: air column detection sensors, contrast tracking, large-injection alert and flow rate and volume.

Around the web

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services.